D. Boral Capital Reiterates Buy Rating for Immunic (NASDAQ:IMUX)

Immunic (NASDAQ:IMUX)‘s stock had its “buy” rating restated by equities research analysts at D. Boral Capital in a report issued on Wednesday,Benzinga reports. They currently have a $8.00 price target on the stock.

IMUX has been the topic of a number of other reports. Chardan Capital upgraded shares of Immunic to a “strong-buy” rating in a research note on Wednesday, November 19th. Weiss Ratings restated a “sell (e+)” rating on shares of Immunic in a research report on Monday, December 29th. HC Wainwright reduced their price target on shares of Immunic from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, November 14th. Roth Capital started coverage on shares of Immunic in a research report on Friday, November 7th. They set a “buy” rating and a $3.00 price objective for the company. Finally, LADENBURG THALM/SH SH upgraded Immunic to a “strong-buy” rating in a research note on Thursday, October 16th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Immunic presently has a consensus rating of “Buy” and a consensus price target of $7.40.

Immunic Price Performance

Shares of NASDAQ:IMUX opened at $0.65 on Wednesday. The business’s 50 day simple moving average is $0.66 and its 200 day simple moving average is $0.79. Immunic has a 1 year low of $0.51 and a 1 year high of $1.39. The company has a market capitalization of $77.59 million, a P/E ratio of -0.78 and a beta of 1.54.

Immunic (NASDAQ:IMUX) last released its earnings results on Thursday, November 13th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.05. On average, sell-side analysts anticipate that Immunic will post -0.94 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Qube Research & Technologies Ltd bought a new position in Immunic during the 3rd quarter worth approximately $29,000. Focus Partners Wealth increased its position in shares of Immunic by 1.5% during the third quarter. Focus Partners Wealth now owns 2,581,587 shares of the company’s stock worth $2,276,000 after buying an additional 39,063 shares during the period. Two Sigma Investments LP bought a new position in Immunic during the third quarter worth $52,000. HB Wealth Management LLC bought a new position in Immunic during the third quarter worth $81,000. Finally, Virtu Financial LLC acquired a new position in Immunic in the third quarter valued at $99,000. 51.82% of the stock is currently owned by institutional investors.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.